Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia

Maurizio Miano, Vincenzo Poggi, Laura Banov, Francesca Fioredda, Concetta Micalizzi, Johanna Svahn, Giovanni Montobbio, Federica Gallicola, Angelo C. Molinari, Rosanna Parasole, Fara Petruzziello, Alain Fischer, Michaela Calvillo, Carlo Dufour

Research output: Contribution to journalArticlepeer-review

Abstract

A 9-month-old boy with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia within the frame of a possible, undiagnosed immune-mediated disease was initially treated with prednisone. Further-line therapies of the following 7 relapses included immunoglobulins, rituximab, cyclophosphamide, and alentuzumab followed by other maintenance treatments as cyclosporine, methotrexate, and mycophenolate. After all the administered therapies failed, the patient was successfully treated by splenectomy followed by fludarabine and then sirolimus as maintenance treatment. Relapses might have been caused by the lack of a complete debulking of triggering cells and/or ineffective maintenance therapy. Splenectomy and sirolimus may have played a complementary role in the management of both situations.

Original languageEnglish
JournalJournal of Pediatric Hematology/Oncology
Volume36
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • autoimmune hemolytic anemia
  • infant
  • pure red cell aplasia
  • Sirolimus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia'. Together they form a unique fingerprint.

Cite this